摘要：DRUG PROFILE - Research programme: coronavirus hybrid vaccines - NuGenerex Immuno-Oncology
Hybrid vaccines based on the Ii-Key peptide vaccine technology are being developed by NuGenerexImmuno-Oncology (previously Antigen Express and wholly-owned subsidiary of Generex) for the prevention of coronavirus infections (2019-nCoV). The proprietary technology utilises the 4-amino acid Ii-Key peptide which is chemically linked to synthetic peptides that mimic as essential epitope of the virus. The Ii-Key peptide by interacting with the allosteric site of MHC Class II molecules causes displacement of the existing antigens and anchors the chemically linked viral epitope to the antigen binding domain. This interaction allows the hybrid vaccine to bypass all requirements for antigen processing and results in enhanced activation of CD4+ T cells and improves long-term immunologic memory. The hybrid vaccine is composed of naturally occurring amino acids which helps in prevention of adverse reactions. Early stage development is ongoing in the US.NuGenerex Immuno-Oncologyis seeking partners for the development of hybrid vaccines for prevention of coronavirus infections (2019-nCoV) (Reference: 809285236).
The use of Antigen Express's Ii-Key technology in the development of immunotherapeutic vaccines is covered by a granted patent in Japan, international counterparts intheUS, Europe, Australia,and China, and a pending application in Canada (Reference: 809133428).
History of Drug Development